Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer

Clinical and Translational Oncology

Volumn 15, Issue 11, 2013, Pages 910-918

  Innamaa, A ^a   Jackson, L ^a   Asher, V ^a   Van Schalkwyk, G ^b   Warren, A ^a   Keightley, A ^b   Hay, D ^a   Bali, A ^b   Sowter, H ^c   Khan, R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF DERBY   (United Kingdom)

Author keywords

Apoptosis; Expression; Ovarian cancer; Potassium channels; TREK 1; TREK 2

Indexed keywords

CURCUMIN; PACLITAXEL; PLATINUM COMPLEX; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNK10; POTASSIUM CHANNEL KCNK2; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; CURCUMIN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; OVARY; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886587480     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1022-4     Document Type: Article

References (30)

1. Cancer Research UK: Ovarian cancer statistics. [Internet]. [Cited: 2012, December]. Available from: http://info.cancerresearchuk.org/cancerstats/ keyfacts/ovarian-cancer/uk-ovarian-cancer-statistics.
2. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006;17(Suppl 5):181-7.
3. Ding XW, Yan JJ, An P, Lu P, Luo HS. Aberrant expression of ether a go-go potassium channel in colorectal cancer patients and cell lines. World J Gastroenterol. 2007;13:1257-61. (Pubitemid 46592971)
4. Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 2003;3:297-302. (Pubitemid 37443884)
5. Voloshyna I, Besana A, Castillo M, Matos T, Weinstein IB, Mansukhani M, et al. TREK-1 is a novel molecular target in prostate cancer. Cancer Res. 2008;68:1197-203. (Pubitemid 351272239)
6. Felipe A, Vicente R, Villalonga N, Roura-Ferrer M, Martinez-Marmol R, Sole L, et al. Potassium channels: new targets in cancer therapy. Cancer Detect Prev. 2006;30:375-85. (Pubitemid 44402898)
7. Nilius B, Schwarz G, Droogmans G. Control of intracellular calcium by membrane potential in human melanoma cells. Am J Physiol. 1993;265(6 Pt 1):1501-10.
8. Pancrazio JJ, Tabbara IA, Kim YI. Voltage-activated K+ conductance and cell proliferation in small-cell lung cancer. Anticancer Res. 1993;13:1231-4. (Pubitemid 23247494)
9. Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS. Inhibition of ATPsensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol. 1995;162:163-71.
10. Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sci. 2008; 29:566-75.
11. Ketchum KA, Joiner WJ, Sellers AJ, Kaczmarek LK, Goldstein SA. A new family of outwardly rectifying potassium channel proteins with two pore domains in tandem. Nature. 1995;376:690-5.
12. Honore E. The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci. 2007;8:251-61. (Pubitemid 46452327)
13. Patel AJ, Lazdunski M, Honore E. Lipid and mechano-gated 2P domain K(+) channels. Curr Opin Cell Biol. 2001;13:422-8.
14. Marklund L, Henriksson R, Grankvist K. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. Int J Cancer. 2001;93:577-83. (Pubitemid 32701418)
15. Shepherd TG, Campbell EL, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc. 2007;1:2643-9.
16. Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, et al. The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010;5:78.
17. Asher V, Warren A, Shaw R, Sowter H, Bali A, Khan R. The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line. Cancer Cell Int. 2011;11:6.
18. Pei L, Wiser O, Slavin A, Mu D, Powers S, Jan LY, et al. Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc Natl Acad Sci USA. 2003;100:7803-7. (Pubitemid 36760050)
19. Wang Z. Roles of K+ channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch. 2004;448:274-86. (Pubitemid 40895596)
20. Patel AJ, Lazdunski M. The 2P-domain K+ channels: role in apoptosis and tumorigenesis. Pflugers Arch. 2004;448:261-73. (Pubitemid 40895595)
21. Lepple-Wienhues A, Berweck S, Bohmig M, Leo CP, Meyling B, Garbe C, et al. K+ channels and the intracellular calcium signal in human melanoma cell proliferation. J Membr Biol. 1996;151:149-57. (Pubitemid 26194256)
22. Nilius B, Wohlrab W. Potassium channels and regulation of proliferation of human melanoma cells. J Physiol. 1992;445:537-48.
23. Tania M, Khan MA, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol. 2010;17:6-11.
24. Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997;28:686-92. (Pubitemid 27258421)
25. Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003;192:161-9. (Pubitemid 36369270)
26. Harguindey S, Orive G. Luis Pedraz J, Paradiso A, Reshkin SJ. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Biochim Biophys Acta. 2005;1756:1-24. (Pubitemid 41317557)
27. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11.
28. Enyeart JA, Liu H, Enyeart JJ. Curcumin inhibits bTREK-1 K+ channels and stimulates cortisol secretion from adrenocortical cells. Biochem Biophys Res Commun. 2008;370:623-8.
29. Park KJ, Baker SA, Cho SY, Sanders KM, Koh SD. Sulfur-containing amino acids block stretch-dependent K+ channels and nitrergic responses in the murine colon. Br J Pharmacol. 2005;144:1126-37. (Pubitemid 40593011)
30. Ditscheid B, Funfstuck R, Busch M, Schubert R, Gerth J, Jahreis G. Effect of Lmethionine supplementation on plasma homocysteine and other free amino acids: a placebo-controlled double-blind cross-over study. Eur J Clin Nutr. 2005;59:768-75. (Pubitemid 40894941)